Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep:44:297-305.
doi: 10.1016/j.jgar.2025.07.011. Epub 2025 Jul 14.

Emerging resistance to novel β-lactam β-lactamase inhibitor combinations in Klebsiella pneumoniae bearing KPC variants

Mase Hamza  1 , German M Traglia  2 , Lucia Maccari  3 , Sonia Gomez  3 , Maria Belen Sanz  3 , Usman Akhtar  1 , Vyanka Mezcord  1 , Jenny Escalante  1 , Alejandra Corso  3 , Cecilia Rodriguez  4 , Christopher R Bethel  5 , Gauri G Rao  6 , Marcelo E Tolmasky  1 , David Paterson  7 , Robert A Bonomo  8 , Fernando Pasteran  3 , Maria Soledad Ramirez  9
Affiliations
Free article

Emerging resistance to novel β-lactam β-lactamase inhibitor combinations in Klebsiella pneumoniae bearing KPC variants

Mase Hamza et al. J Glob Antimicrob Resist. 2025 Sep.
Free article

Abstract

Objective: Klebsiella pneumoniae carbapenemase (KPC) variants, predominantly KPC-2 and KPC-3, are significant global resistance mechanisms, conferring resistance to many β-lactams, including carbapenems, while remaining susceptible to ceftazidime-avibactam (CZA). Recently, new KPC variants have developed resistance to CZA through mutations, insertions, or deletions in regions such as the Ω-loop, 240-loop (237-243 aa), and 270-loop (266-275 aa). This study investigated collateral resistance to cefiderocol (FDC) and cefepime/zidebactam (FPZ) in isolates with these mutations.

Methods: Fifteen clinical KPC-producing Klebsiella spp. isolates representing 15 distinct variants were analysed. Antimicrobial susceptibility testing determined the MICs for CZA, carbapenems, FDC, FPZ, and other antibiotics. Synergy between CZA and FDC was assessed. Whole-genome sequencing (WGS) was used to identify resistance-related mutations.

Results: CZA resistance was confirmed in 12/15 variants. Collateral resistance to FDC occurred in eight isolates, with five exhibiting spontaneous resistant subpopulations. Six FDC-resistant strains had mutations in the 270-loop (266-275 aa). FPZ resistance was seen in three KPC variants, especially those with mutations in the 270-loop, though many Ω-loop and 240-loop (237-243 aa) mutants remained susceptible. WGS of FDC-resistant subpopulations revealed additional mutations in ompC, rpoC, dksA, and cirA.

Conclusions: Emerging CZA-resistant KPC variants often exhibit collateral FDC resistance, with FPZ seen less frequently. Mutations in blaKPC, cirA, and other genes contribute to resistance. Understanding these emerging resistant patterns linked with new KPC variants is crucial to inform therapeutic decisions, as emerging resistance may limit last-line treatment options in clinical settings.

Keywords: Cefiderocol; Ceftazidime/avibactam; Collateral resistance; KPC; Zidebactam.

PubMed Disclaimer

Update of

MeSH terms